Who are Placebo PF00299804's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Capecitabine combined with Pyrotinib, TKI, Dacomitinib (PF-00299804).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-pf00299804.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo PF00299804 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo PF00299804 (Placebo PF00299804) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR/HER2 tyrosine kinase inhibitor. Area: Oncology.

phase 3 EGFR/HER2 tyrosine kinase inhibitor EGFR, HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo PF00299804 (Placebo PF00299804) — Pfizer. PF00299804 is a small-molecule tyrosine kinase inhibitor that targets EGFR and HER2 to block cancer cell growth signaling.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo PF00299804 TARGET	Placebo PF00299804	Pfizer	phase 3	EGFR/HER2 tyrosine kinase inhibitor	EGFR, HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Capecitabine combined with Pyrotinib	Capecitabine combined with Pyrotinib	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Combination chemotherapy and tyrosine kinase inhibitor	Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib)
TKI	TKI	Shenzhen TargetRx Co., Ltd.	phase 3	Tyrosine kinase inhibitor	Tyrosine kinases (e.g. EGFR, HER2, BCR-ABL)
Dacomitinib (PF-00299804)	Dacomitinib (PF-00299804)	Pfizer	phase 3	Pan-HER tyrosine kinase inhibitor	EGFR, HER2, HER4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR/HER2 tyrosine kinase inhibitor class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo PF00299804 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-pf00299804. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing